Latest Mdm2 Stories
A large proportion of late-stage breast cancers that have spread to other parts of the body (metastatic breast cancers) are characterized by overexpression of the protein Mdm2.
The small-molecule inhibitor nutlin-3 may be a viable treatment option for neuroblastoma patients with wild-type p53 activity.
Aggressive tumors lacking p53 protein stop dead in their tracks when p53's sister protein -- TAp63 -- steps in.
A tumor-suppressing protein snatches up an important cancer-promoting enzyme and tags it with molecules that condemn it to destruction, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports this week in the journal Molecular Cell.
A Purdue University scientist has discovered a key process in cell growth that can lead to the formation of tumors. Xiaoqi Liu, an assistant professor of biochemistry.
A tightly controlled system of checks and balances ensures that a powerful tumor suppressor called p53 keeps a tight lid on unchecked cell growth but doesn't wreak havoc in healthy cells.
Researchers at The University of Texas M. D. Anderson Cancer Center have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells.
Researchers may have found a more potent risk factor for melanoma than blistering sunburns, freckling, or family history of the deadly skin disease.
University of Rochester Medical Center scientists discovered a gene mutation that impairs the placenta and also is influential in cancer development.
A variation of a cancer-causing gene called SNP309 interacts with an anti-cancer gene, known as p53, to influence a woman's odds of surviving breast cancer, according to a report in the Journal of the National Cancer Institute.